丝裂霉素膀胱灌注热化疗联合瑞柯恩钬激光电切对非浸润性膀胱癌患者血清Dickkopf-1及α-FR的影响  

Effect of mitomycin bladder perfusion thermochemotherapy combined with Recoen holmium laser resection on the expression of serum Dickkopf-1 andα-FR in patients with non-invasive bladder cancer

作　　者：潘润阳 王顺民 苏文星 张剑平 林荣凯 Pan Runyang;Wang Shunmin;Su Wenxing;Zhang Jianping;Lin Rongkai(Department of Urology,the 910th Hospital of the Joint Service Support Force of the People′s Liberation Army,Quanzhou 362000,China)

机构地区：[1]解放军联勤保障部队第910医院泌尿外科,泉州362000

出　　处：《国际泌尿系统杂志》2024年第1期28-33,共6页International Journal of Urology and Nephrology

基　　金：河北省卫生健康委医学科学研究课题计划项目(20201131)。

摘　　要：目的探讨丝裂霉素膀胱灌注热化疗联合瑞柯恩钬激光电切对非浸润性膀胱癌患者血清Dickkopf-1及α-叶酸受体(alpha-folate receptor, α-FR)表达的影响。方法选取2017年5月至2020年1月于本院就诊并接受治疗的136例非浸润性膀胱癌患者为研究对象, 采用随机数字表法将其分为对照组和观察组, 每组各68例。对照组给予瑞柯恩钬激光电切治疗, 观察组给予丝裂霉素膀胱灌注热化疗联合瑞柯恩钬激光电切治疗, 对比两组患者治疗2个月前后的临床疗效、免疫功能相关指标、血清Dickkopf-1和α-FR水平、不良反应、复发及远期生存情况。结果治疗2个月后对照组的控制率为55.88%(38/68), 缓解率为79.41%(54/68);观察组的控制率为79.41%(54/68), 缓解率为94.12%(64/68), 两组差异均有统计学意义(均P<0.05)。治疗2个月后观察组的体液免疫细胞指标(免疫球蛋白A、免疫球蛋白G和免疫球蛋白M)、CD4+和CD4+/CD8+水平均明显高于对照组, 观察组的CD8+水平明显低于对照组, 差异均有统计学意义(均P<0.05)。治疗后两组的血清Dickkopf-1和α-FR水平均显著降低, 且观察组的血清Dickkopf-1和α-FR水平明显低于对照组, 差异均有统计学意义(均P<0.05)。治疗2个月内对照组的总不良反应发生率为22.06%(15/68), 观察组的总不良反应发生率为19.12%(13/68), 但差异无统计学意义(P>0.05)。观察组治疗后的2年内复发率显著低于对照组(P<0.05)。结论丝裂霉素膀胱灌注热化疗联合瑞柯恩钬激光电切治疗非浸润性膀胱癌效果显著, 可增强抗肿瘤作用, 有效改善临床疗效、机体体液免疫和细胞免疫功能, 降低血清Dickkopf-1和α-FR水平, 提高疾病控制率和缓解率, 且未增加不良反应。Objective The effect of mitomycin bladder perfusion thermochemotherapy combined with Recoen holmium laser electrotomy on the expression of serum Dickkopf-1 and alpha-folate receptor(α-FR)in patients with non-invasive bladder cancer.Methods From May 2017 to Jan 2020,136 patients with non-invasive bladder cancer who were treated in our hospital and all patients were divided into control group and observation group by random number table method,with 68 people in each group.The control group was treated with Recoen holmium laser resection,and the observation group was given mitomycin bladder perfusion thermochemotherapy combined with Recoen holmium laser resection.The clinical efficacy,immune function-related indexes,serum Dickkopf-1 andα-FR levels,adverse reactions and recurrences,and long-term survival 2 months before and after treatment.Results After 2 months of treatment,the control rate of the control group was 55.88%(38/68),and the remission rate was 79.41%(54/68),the control rate of the observation group was 79.41%(54/68),and the remission rate was 94.12%(64/68).The differences in control rate and remission rate between the two groups were statistically significant(all P<0.05).After 2 months of treatment,the humoral immune cell indicators(immunoglobulin A,immunoglobulin G and immunoglobulin M),CD4+and CD4+/CD8+levels of the observation group were significantly higher than those of the control group,and the CD8+level of the observation group was significantly lower Control group(all P<0.05).After treatment,the serum Dickkopf-1 andα-FR levels of the two groups were significantly reduced,and the serum Dickkopf-1 andα-FR levels of the observation group were significantly lower than those of the control group(all P<0.05).In addition,the differences in serum Dickkopf-1 andα-FR levels between the two groups before and after treatment were statistically significant(all P<0.05).Within 2 months of treatment,the total adverse reaction rate in the control group was 22.06%(15/68),and the total adverse reaction rate in

关 键 词：膀胱肿瘤 丝裂霉素 膀胱灌注 膀胱切除术 DICKKOPF-1 α-FR 

分 类 号：R737.14[医药卫生—肿瘤]